Clinical Trials in Larissa, Thessaly
18 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Merck Sharp & Dohme LLC780 enrolled260 locationsNCT06312137
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled215 locationsNCT06345729
Recruiting
Oxidative Stress in Autoimmune Rheumatic Diseases
Psoriatic Arthritis (PsA)Ankylosing Spondylitis (AS)Rheumatoid Arthritis (RA)+1 more
University of Thessaly200 enrolled1 locationNCT07536529
Recruiting
Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Merck Sharp & Dohme LLC680 enrolled231 locationsNCT06623422
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled257 locationsNCT06841354
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled258 locationsNCT06312176
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Sickle Cell DiseaseThalassemia
Novo Nordisk A/S480 enrolled103 locationsNCT06609226
Recruiting
Phase 2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
MyelofibrosisModerate ThrombocytopeniaMild Thrombocytopenia
Karyopharm Therapeutics Inc58 enrolled70 locationsNCT05980806
Recruiting
Observational Study Protocol: LIVER-R
Hepatobiliary Cancers
AstraZeneca4,490 enrolled138 locationsNCT06252753
Recruiting
Role of Tryptase Levels in Patients With Stable Coronary Artery Disease.
Chronic Coronary Syndrome
University of Thessaly200 enrolled2 locationsNCT06958016
Recruiting
Not Applicable
l Investigation of Robotic-assisted TKA (RA-TKA) With Skywalker and Evolution Medial Pivot Knee (eMP Knee)
Orthopaedic Department of General University Hospital of Laria122 enrolled1 locationNCT06969222
Recruiting
Frailty, Hip Fractures and Inflammatory Biomarkers
FrailtyHip FractureInflammatory Biomarkers
University of Thessaly200 enrolled2 locationsNCT06614478
Recruiting
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
Ischemic Stroke
Insel Gruppe AG, University Hospital Bern2,800 enrolled33 locationsNCT06556446
Recruiting
Phase 4
Tapentadol vs Tramadol in Total Knee Arthroplasty
Total Knee Replacement
University of Thessaly96 enrolled1 locationNCT06269770
Recruiting
Not Applicable
Aminoglycoside Administration in Septic Patients
SepsisSeptic ShockAminoglycoside Toxicity
University of Thessaly50 enrolled1 locationNCT06226441